[1] BRINK A J. Epidemiology of carbapenem-resistant Gram-negative infections globally[J]. Curr Opin Infect Dis, 2019, 32(6):609-616. doi:  10.1097/QCO.0000000000000608
[2] 周海英, 曹原, 邓劲, 等. 氨曲南联合头孢他啶/阿维巴坦对产金属β-内酰胺酶肠杆菌目细菌的体外协同作用初探[J]. 中国抗生素杂志, 2021, 46(8):784-788.
[3] HOANG C Q, NGUYEN H D, VU H Q, et al. Emergence of new Delhi metallo-beta-lactamase (NDM) and Klebsiella pneumoniae Carbapenemase (KPC)production by Escherichia coli and Klebsiella pneumoniae in southern Vietnam and appropriate methods of detection: a cross-sectional study[J]. BioMed Res Int, 2019, 2019:9757625.
[4] 胡付品, 郭燕, 朱德妹, 等. 2021年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2022, 22(5):521-530.
[5] MA J Y, SONG X R, LI M C, et al. Global spread of carbapenem-resistant Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy[J]. Microbiol Res, 2023, 266:127249. doi:  10.1016/j.micres.2022.127249
[6] SHARIFIPOUR E, SHAMS S, ESMKHANI M, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU[J]. BMC Infect Dis, 2020, 20(1):646. doi:  10.1186/s12879-020-05374-z
[7] ABDELAZIZ S M, ABOSHANAB K M, YAHIA I S, et al. Correlation between the antibiotic resistance genes and susceptibility to antibiotics among the carbapenem-resistant gram-negative pathogens[J]. Antibiotics, 2021, 10(3):255. doi:  10.3390/antibiotics10030255
[8] 孙艳, 多丽波. 耐碳青霉烯类肠杆菌科细菌耐药机制及实验室检测研究进展[J]. 国际检验医学杂志, 2020, 41(16):2011-2016.
[9] Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing, 32nd edition [S].http://standards/products/microbiology/companion/using-m100/[2022-03-09].
[10] Centers for Disease Control and Prevention (CDC). Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE)[EB/OL]. (2020-07-01)[2022-01-10]. https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf.
[11] 杨启文, 马筱玲, 胡付品, 等. 多黏菌素药物敏感性检测及临床解读专家共识[J]. 协和医学杂志, 2020, 11(5):559-570.
[12] RANJBAR R, ALAM M. Antimicrobial Resistance Collaborators(2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis[J]. Evid Based Nurs, 2024, 27(1):16. doi:  10.1136/ebnurs-2022-103540
[13] GANDRA S, BURNHAM C A D. Carbapenem-resistant enterobacterales in the USA[J]. Lancet Infect Dis, 2020, 20(6):637-639. doi:  10.1016/S1473-3099(20)30066-9
[14] HANSEN G T. Continuous evolution: perspective on the epidemiology of carbapenemase resistance among enterobacterales and other gram-negative bacteria[J]. Infect Dis Ther, 2021, 10(1):75-92. doi:  10.1007/s40121-020-00395-2
[15] 李鑫, 杨继勇. 碳青霉烯类耐药肠杆菌科细菌分布与流行特征研究进展[J]. 中华微生物学和免疫学杂志, 2019, 39(4):306-310.
[16] CASTANHEIRA M, DESHPANDE L M, MENDES R E, et al. Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents[J]. JAC Antimicrob Resist, 2022, 4(5):dlac098. doi:  10.1093/jacamr/dlac098
[17] PORRECA A M, SULLIVAN K V, GALLAGHER J C. The epidemiology, evolution, and treatment of KPC-producing organisms[J]. Curr Infect Dis Rep, 2018, 20(6):13. doi:  10.1007/s11908-018-0617-x
[18] HAN R R, SHI Q Y, WU S, et al. Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China[J]. Front Cell Infect Microbiol, 2020, 10:314. doi:  10.3389/fcimb.2020.00314
[19] 朱丰村, 曾云祥, 金晓立, 等. 204株碳青霉烯类耐药肠杆菌目细菌耐药性分析[J]. 检验医学, 2023, 38(1):60-65.